Acutaas Chemicals Limited has notified the stock exchanges of a senior-level personnel change, disclosing the resignation of Mr. Trilok Vasant Sontakke from his role as Senior General Manager – Technical Support Department. The intimation, filed on May 18, 2026, was made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Details of the Resignation

Mr. Sontakke, who also held the designation of Senior Management Person at Acutaas Chemicals Limited, submitted his resignation letter dated May 12, 2026, addressed to Mr. Ram Mohan Lokhande, Whole Time Director of the company. The resignation was received and accepted on the same date. The following table summarises the key disclosures made under the applicable SEBI regulations:

Regulatory Compliance

The disclosure was filed in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The intimation was signed and submitted by CS Ekta Kumari Srivastava, Company Secretary and Compliance Officer of Acutaas Chemicals Limited, on May 18, 2026. The company has confirmed that the requisite annexures and details as required under the applicable regulatory framework have been provided to the exchanges.

Acutaas Chemicals has reported its financial results for the fourth quarter and fiscal year ended March 31, 2026. The company achieved its highest ever Profit After Tax (PAT) of INR356.4 crores for FY26, with revenue from operations reaching INR1,339.4 crores. Building on this strong performance, the management has expressed confidence in delivering 25% revenue growth in FY27.

Financial Performance for FY26

The company closed the fiscal year with robust financial metrics, reflecting significant year-on-year growth. The Managing Director highlighted that the results demonstrate the strength of their business model and disciplined execution.

Strategic Initiatives and Growth Drivers

Management outlined progress across multiple verticals to support future growth. In the battery chemicals business, the company has commercialized its first two products and expects to bring two additional products to commercial scale in FY27. The semiconductor business, particularly through BFC, is gaining traction with new products expected to contribute meaningfully in the coming year. Additionally, the R&D centre for the South Korea joint venture, Indichem, is operational and has started sending samples to prospective customers.

FY27 Outlook and Guidance

Acutaas Chemicals has guided for 25% revenue growth in FY27. This projection is backed by a strong pipeline across all three verticals: pharmaceutical intermediates, battery chemicals, and semiconductors. The management indicated that while near-term cost pressures from global supply chain disruptions exist, they are confident in maintaining EBITDA margins at levels similar to FY26. The company also noted that its existing infrastructure is well-positioned to support growth through FY28.